Introduction
Glioma is the most common and aggressive brain tumor that accounts for high rates of cancer-related mortality. 1, 2 Even with aggressive treatment, therapy resistance and tumor recurrence occur in a majority of patients. 3, 4 Thus, there is a clear need to develop new therapeutic strategies to improve outcome for glioma patients.
The current standard of treatment for glioma is surgical resection followed by radiation treatment. 5 Radiation therapy has been demonstrated as an effective tool for glioma, which is usually applied in a course of multiple fractions over weeks to reduce the normal cell toxicity. 3, 6 The rationale of using radiation to treat glioma is based on the fact that the proliferating glioma cancer cells are more sensitive to the radiation treatment than normal astrocytes. 7 However, the exact mechanisms underlying the differential response between glioma cells and normal astrocytes have remained elusive. Understanding these mechanisms is critical for improvement of radiation treatment by both enhancing the cytotoxicity to glioma cancer cells and reducing the side effects to normal astrocytes.
On the other hand, glioma cells develop radiation resistance to enhance survival by regulating signaling pathways involving cancer stem cells, 8, 9 hypoxia, 10 proliferation, submit your manuscript | www.dovepress.com
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gong et al infiltration and angiogenesis. 12 Some of these share the similar mechanism with normal astrocytes. 7 For example, normal cells are less sensitive than rapidly proliferating cancer cells for the DNA damage response. 1 The glioma cells develop radiation resistance by a similar mechanism that they overexpress effectors, such as ATM, ATR, Chk1, Chk2 and Rad17, to activate P53 or inactivate cyclin-dependent kinases, thereby halting cell cycle progression and starting DNA repair. 13 Thus, improvement of our understanding about the differential responses between normal astrocytes and glioma cells is necessary for developing radiosensitizers for glioma.
In this study, to explore the underlying molecular mechanisms of differential response between normal astrocytes and glioma cells, we characterized the transcriptome profile of a radiation-treated and nontreated normal astrocyte cell line (human astrocyte [HA] ) and glioma cell line (U251) by nextgeneration sequencing. Our results pointed to potential pathways related to radiation resistance of glioma cells and identified the critical role of Hippo/YAP signaling pathway in this process.
Material and methods cell culture and radiation treatment
U251 and SNB19 cells were purchased from American Type Culture Collection (ATCC) were cultured in Eagle's Minimum Essential Medium (EMEM) (Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 2 mM glutamine, 1% nonessential amino acids, 1 mM sodium pyruvate and 10% fetal bovine serum. HA cell line was purchased from ScienCell™ Research Laboratories and was cultured in the astrocyte medium (Gibco) with 10% fetal bovine serum and 1% penicillin/streptomycin and was maintained at 37°C in an air atmosphere. Radiation was performed using an RS-2000 biological irradiator (Rad Source Technologies, Inc., Suwanee, GA, USA) with 160 kV X-rays with a 0.3 mm copper filter at a dose rate of ~1.2 Gy/min.
experiment design for comparative transcriptome study
To explore the radiation response of HA and U251 cells at the molecular level, transcriptome profiles of radiationtreated and nontreated HA and U251 cells were characterized by next-generation sequencing. As shown in Figure 1 , the differentially expressed genes (DEGs) between radiationtreated and nontreated HA cells were named DEG1. Similarly, the DEGs between radiation-treated and nontreated U251 cells were named DEG2. The DEGs between normal HA and U251 cells were named DEG3. The DEGs between radiation-treated HA and U251 cells were named DEG4.
cell viability assay and growth curve generation
The cells were seeded into 96-well plates at a density of 3,000 cells/well. After attachment, the cells were treated with or without 10 Gy radiation. After another 24 or 48 hours of culture, cell number was measured by cell counting kit-8 (CCK-8; Sigma-Aldrich Co., St Louis, MO, USA) according to the manufacturer's manual. For growth curve generation, cells in the wells of three parallel plates were subjected to CCK-8 analysis every 12 hours. Population doubling level (PDL), the number of times cells double their population during a given time period, was calculated using the following formula: PDL (log 10 F -log 10 I)/log, where F indicates cell numbers at the end of the passage and I equals cell numbers initially plated. Population doubling (PD) time was calculated by the formula: hours in culture/PDL.
colony formation assay
The cells were plated into six-well plates or 35 mm dishes. After treatment with or without 10 Gy radiation, the cells were cultured for another 15 days. For visualization, the cells were stained by crystal violet. The colonies .50 cells were counted under a dissecting scope. For statistics, the number of colonies was normalized to the control group.
Total rna extraction
Total RNA was extracted using RNeasy Mini Kit (Qiagen NV, Venlo, the Netherlands) according to the manual. In brief, up to 1×10 7 cells were disrupted in lysis buffer and homogenized. Ethanol was added into the lysate. The sample was then applied to the RNeasy Mini Spin Column and eluted in RNase-free water. For RNA sequencing and cell-based experiment, the total RNA from the cells was prepared for analysis 1 hour after 2 Gy of radiation treatment. Notes: ha and U251 cells were treated with 2 gy dose of radiation. The rnas were prepared 1 hour after treatment. next-generation sequencing was used to generate transcriptome profiles. DEG1 and DEG2 represent the differentially expressed mrnas and lncrnas in radiation-treated ha and U251 cells compared with their control counterparts. Deg3 refers to transcriptome differences between ha and U251 cells without any treatment. Deg4 represents transcriptome differences between radiation-treated ha and radiation-treated U251 cells. Abbreviations: ha, human astrocyte; Deg, differentially expressed gene.
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Differential radiation response between has and glioma cells cDna library construction, sequencing and quality control RNA fragments were randomly broken into short fragments. The first chain of cDNA was generated using RNA fragments as templates and 6 bp random primers. The second chain of the cDNA was synthesized following the kit's manual (Takara, Dalian, China). Base A and sequencing joint were added into purified and end-repaired cDNA, followed by fragmentation with uracil N-glycosylase (UNG). After screening by size, polymerase chain reaction (PCR) amplification was performed to establish the complete sequencing cDNA library. Both mRNAs and lncRNAs were sequenced with HiSeq 2500 sequencer (Illumina, San Diego, CA, USA). Trim Galore software was used to dynamically remove joint sequence fragments and low-quality segments from the 3′-end. FastQC software was used for quality control.
Total number of reads, read length distribution and the nucleotide distribution across cycles were used as quality control for sequencing experiments.
14,15 For a perfect sequencing run, the distribution of the four nucleotides (A, T, C and G) across all reads should remain relatively stable. 16 As shown in Figure S1 and Tables S1 and S2, the total number of reads, high-quality reads and alignment results were reliable. In addition, as shown in Figure S2A -D, except for the 5′-end unbalanced composition preference caused by the random primer, the frequency of reads in every position (A, T, C and G) is close to 25%.
sequence alignment and assembly of transcripts
TopHat software was used to align RNA-seq reads to the reference genome. Genome Homo_sapiens.GRCh37 was chosen as the reference genome and was downloaded from the website ftp://ftp.ensembl.org/pub/release-73/fasta/homo_ sapiens/dna/. Homo_sapiens.GRCh37.74.gtf, the location information of known transcripts in the genome, was downloaded from the website ftp://ftp.ensembl.org/pub/release-73/ gtf/homo_sapiens/Homo_sapiens.GRCh37.73.gtf.gz. The alignment parameters included: 2 bp mismatch was allowed, maximal 20 bp match records for every read, considering the variable shear, the length of segment as 25 bp, maximal mismatch number in every fragment as 2 bp, maximal insert and deletion length as 3 bp, alternative splicing position must be aligned completely, minimum intron length as 50 bp and maximum intro length as 50,000 bp. For each sample, Cufflinks software was used for assembly of transcripts based on location information of known transcripts in the genome.
Bioinformatics analysis and statistical analysis
Pathway analysis and gene ontology (GO) classification were performed using iPathwayGuide online bioinformatics tool (https://apps.advaitabio.com). 17 GO clustering was performed by DAVID online software (https://david.ncifcrf. gov/). 18 YAP gene expression data were downloaded from R2: Genomics Analysis and Visualization Platform (http:// r2.amc.nl). The R2 program was used to generate a KaplanMeier survival curve (http://r2.amc.nl).
real-time Pcr
Total RNA was isolated from cells by TRIzol reagent (Thermo Fisher Scientific). Complementary DNA was synthesized by reverse transcription using PrimeScript RT reagent kit (Takara). Real-time PCR was performed with gene-specific primers in the presence of CYBR green reagents. Relative abundance of mRNA was calculated by normalization to GAPDH mRNA. Information on primers is shown in Table S3 .
Plasmids, shrnas and reagents
Two independent small hairpin (sh) RNAs (Table S4) against YAP were used for the experiments and were cloned into PLKO.1 vector. All other common reagents were purchased from Sigma-Aldrich Co.
lentiviral generation and infection
Lentiviruses were generated using Lenti-X Packaging Single Shots (Clontech, Palo Alto, CA, USA) according to the manufacturer's procedures. Media containing lentivirus were used to infect the cells. A stable cell line was selected by culturing in complete media containing puromycin for 10 days. Knockdown and overexpression efficiency were determined by Western blot.
immunoblotting Cells were lyzed using radioimmunoprecipitation assay (RIPA) reagents (Thermo Fisher Scientific). The lysates were centrifuged for 10 min at 4°C. The supernatants were used for immunoblotting. Immunoblotting was performed using standard protocol. Information for antibodies is shown in Table S5 .
statistical analysis
The data represent mean ± SD from three independent experiments except where indicated. Data analysis was performed using the Student's t-test on raw data with Statistical Package of the Social Sciences (SPSS; SPSS Inc., Chicago, IL, USA) at a significance level of P,0.05. 
Results
establishment of in vitro model for normal astrocytes and glioma cells
Normal HA and U251 cell lines were used as models for normal astrocytes and glioma cells. We first measured their growth curves. As shown in Figure S3A , HA cells grow more slowly than U251 cells. The PD times of HA and U251 cells were 33.2 and 25.1 hours, respectively. Next, to confirm their differential radiation responses, we performed cell viability and colony formation assays. As shown in Figure S3B , the result from the cell viability assay showed that radiation treatment resulted in a significantly higher reduction in cell number of U251 cells than HA cells. Consistently, a similar result was obtained by long-term colony formation assay ( Figure S3C ), which suggested that HA cells are more tolerant to radiation treatment than U251 cells. These results demonstrated that HA and U251 cells could serve as in vitro models for normal astrocytes and glioma cells.
comparative analysis of the transcriptome of radiation-treated and nontreated ha and U251 cells
To explore the differential radiation responses of HA and U251 cells at the molecular level, the transcriptome profiles of radiation-treated and nontreated HA and U251 cells were characterized by next-generation sequencing. In total, we identified 296 and 262 differentially expressed mRNAs ( Figure 2A ) and lncRNAs (Table S6) , respectively, between radiation-treated and nontreated HA cells. In addition, we identified 201 and 139 differentially expressed mRNAs ( Figure 2B ) and lncRNAs (Table S7) , respectively, between radiation-treated and nontreated U251 cells. RNA5SP233  COL6A2  MDM2  DKK3  TNS1  ACTB  MED26  CA6  C19orf44  PKM  YPEL3  NR5A2  RASGEF1C  IP6K2  SCRIB  AFF2  MEX3D  PCGF2  THOP1  CDH24  RBM42  FOXJ3  C9orf64  EVA1A  CSRNP1  USP33  MANSC1  HNRNPAB  ANGEL2  AGPAT1  TOR1AIP1  ZNF503  FAM217B  PTPRM  NBEAL2  SLC12A4  NDRG3  ZNF33A  UBE2Q2  ADARB1  CAPN1  MARVELD1  SMOX  DYRK1B  MLLT10  YIPF5  TSC1  SCAF4 TOLLIP  EPB41L2  PTCHD1  PLEKHM2  OAZ2  MT-ND6  TMEM212  MAB21L3  PARP15  MED18  UGT8  SHISA9  C12orf55  AL590867.1  ABCC9  PLEC  HSPG2  AHNAK  LRR1  MYADM  ZNF329  AMOTL2  GUCD1  MSRB3  RABGAP1L  CDH24  ATP8B1  CORO1B  TAB3  EP400  TPST2  NBEAL2  OSBPL10  DPP3  FAM213A  ALYREF  RASSF8  GSN  USP28  SLC44A1  UIMC1  NTN1  SERPINB6  PLD3  SMOX  DHX57  SCAF4  PRPF38B NFRKB COL14A1 CXorf56  MGEA5  NFAT5  TMEM104  ZNF521  ATP7B  HIVEP2  ZNF33A  IFT172  RASSF2  SMARCA1  BAHD1  MSH6  ZBTB43  SEC14L1  USP40  TRIM26  C12orf57  ABCF1  PIGU  RFX5  RALB  SPAST  PSPH  GZF1  DZIP1  RHBDF2  NBR1  SCAMP2  CAPN10  HP1BP3  PUF60  PLXNB1  PSMA6  ITPK1  ZCCHC6  TSPAN9  COX18  WDR11  GDF5  DYRK1B  MTF2  MID1  WDR44  OCRL  DOCK10  SORBS2  HMCN1 ABLIM1  ANAPC4  PSTPIP2  SMARCD1  CYTH1  PHKB  SHANK3  CES1  MCM3  FAM188A  CKAP5  MICA  ENSA  C3orf17  TBL1X  MTRF1L  DYNC1I2  INTU  RABEPK  LANCL1  RP4-604K5.1  MORC3  WARS  TMEM63B  DSTYK  SRGAP2  AGPAT4  HLCS  NACA  BDP1  ATP1A1  USP19  LGALS3BP  FAM179B  RALGAPB  YOD1  AMOT  PLOD2  ALAS1  POLR3B  ELMO2  TINF2  USP33  SEC23A  BCKDK  FILIP1L  RFC1  RBBP7 ATR FAM57A LGR4  HSDL2  PHTF1  ACAA1  GCSH  NINJ1  CHD4  MMGT1  YIPF5  KLHL25  MAP3K4  PIP4K2C  PDHB  ZNF532  PUM1  CDK9  AHSA1  GLB1  XPNPEP1  COPB1  PEPD  RNF6  NBAS  PTTG1  ZWILCH  FBF1  SMIM7  CRYZL1  BCHE  SPC24  SPARC  DDX60L  EIF4G1  OLFML2B  LRTOMT  NRP2  PARP2  DST  FLNA  NXT2   TGFBI  MAPK3  AP2M1  POLR2H  RNF170  NUMA1  TGFBI  IPO9 -120P  STAT2  FBLIM1  USP7  ANKLE2  RNVU1-6  IST1  RNA5SP44  PTPRF  PSME4  GAS6  ILF3  ATP2A2  DDX6  SNORA74  HMGB1  MYLK  MATR3  ITGAV  CTSB  SET  ARPC2  RPL7  TPT1  TPM1  MIR604   RNU2-37P  NOTCH3  EPS15L1  ACTG1  MRPL50  MAP1B  TGFBI  ITGA3  ALG14  DST  TTK  AL603650.4  SOGA2  POLR1A  FLNA  SRRT  KCNMA1  SOGA1 
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In addition, there were 124 and 260 differentially expressed mRNAs ( Figure S4A ) and lncRNAs (Table S8) , respectively, between nontreated HA and U251 cells. Whereas, there were 193 and 100 differentially expressed mRNAs ( Figure S4B ) and lncRNAs (Table S9) , respectively, between radiation-treated HA and U251 cells. Furthermore, five genes ( Figure 2C ) and 13 lncRNAs ( Figure S5 ) were oppositely regulated by radiation in HA and U251 cells, which may represent the major differential radiation responses between HA and U251 cells.
gO and pathway analyses of Degs
To further investigate the functional roles of the DEGs, we performed GO and pathway analyses. As shown in Figure 3A and B, GO analysis showed that radiation causes alterations in similar functional modules in HA and U251 cells, including cellular component organization, ion binding, membrane and vesicle, which suggested that the major effects of radiation on HA and U251 cells were similar. As shown in Figure S6A and B, the DEGs between normal HA and U251 cells and between radiation-treated HA and U251 cells were also enriched in similar functional modules, including cellular component organization, ion binding, RNA binding, membrane and vesicle, which confirms the finding that radiation treatment leads to similar alterations in HA and U251 cells. Next, pathway analysis of the DEGs was performed. In HA cells, radiation treatment altered genes involved DCUN1D4  TRIM32  RPL7  DLAT  FAM117B  AFF1  COBLL1  TEAD1  FAM60A  SLC25A19  LYRM4  TRAPPC6B  PUM2  IGSF3  ATP11C  HNRNPH1  AGL  CYLD  IFIT3  CPEB4  MAP2K4  ATP2B1  PPP1CB  RNF38  NEK6  TXNRD1  OSBPL8  IBTK  ETS1  MPDU1  PRKDC  SQSTM1  RPLP1  ANXA2  TFRC  FLCN  PARP2  DDX60L  UBC  POLR2H  EIF4G1  ANXA2  ZWILCH  TCOF1  SOGA2  CDCA7L  NUP155  GNAI2   HDGF  VOPP1   PRC1  HYOU1   L o g 2  U 2 5 1 -2 G y /   U 2 5 1  LARS  MOGS  ZNF24  ZNF561  TBC1D7  MFSD6  ZMYND11  PTPN21  SPATS2  DNPEP  BABAM1  PPP2R1A  ATG4C  DNMT1  PKN1  RB1CC1  ABCA7  PPIP5K2  EPB41L5  CEP170  C6orf70  SLBP  MORC3  OPTN  POLR3G  SCAF8  CUL4A  MID1  ZSCAN25  TMEM117  CENPI  YWHAZ  LIAS  MRS2  RAB3GAP1  GSE1  SPOP  C3orf17  SMC2  DPY19L3  TTPAL  SMG7  PLD3  RAB34  BID  SDCBP  GGCX  ZNF530  ZFX   L o g 2  U 2 5 1 -2 G y /   U 2 5 1  RBMX  PLD3  GRIK2  RAP1GAP2  NAGA  PARK7  TRPS1  PLAUR  DHX40  HRAS  TUBGCP2  TLK1  NR3C1  ELP3  CNOT8  DGKH  PLK4  BAZ1A  SRRM1  BRCA2  MED18  SCAF1  PRR12  TNRC18  MT-ND6  ATN1  OPHN1  MAB21L3  ABCC9  ANXA2  RPS27  ACTB  SCRIB  SRP9  MZT1  SNRPG  SEC61G  KIAA1522  VARS2  EVI5  TLE2  TIMP2  NCOR2  ZMIZ2  REV3L  DDR1  SEC31A  CLPTM1L  ZNF786 L o g 2 U 2 5 1 -2 G y / U 2 5 1  MT-TC  ANXA2  RPL29  CAV1  ACTN1  TUBA1A  COL6A2  CALD1  AXL  ILF3  SLC39A14  NCOA4  NEDD9  ANXA2  FEZF2  LILRA5  COL21A1  CDIPT  KCTD13  POLR2H  FAM131A  HDLBP  NFIC  IMPDH1  RRBP1  LATS2  OS9  ST3GAL1  HTATSF1  RNF166  SEC16A  STON2  LMNA  BTN2A1  ADD2  EFR3B  HOXB3  LITAF  CDK7  CABIN1  MTHFR  DOCK11  DIDO1  CYB561  NOC3L  FOXJ3  TRAPPC11  CEP128  TMEM41B  BMPR1B L o g 2 U 2 5 1 -2 G y / Figure 4A ). In U251 cells, genes regulated by radiation treatment are mostly distributed in Hippo, cell cycle, central carbon metabolism in cancer and VEGF signaling pathways ( Figure 4B ). In addition, genes differentially expressed between HA and U251 cells (including both normal and radiation treated) are mostly involved in P53, TGF-β, VEGF, Jak-STAT, Hippo, regulation of actin cytoskeleton and tight junction signaling pathways ( Figure S7A and B) . Interestingly, we found that the activation status of Hippo signaling pathway is different between HA and U251 cells. Several key genes in the Hippo pathway, such as SCRIB, are oppositely regulated by radiation treatment ( Figure 2C ) in HA and U251 cells. Hippo signaling pathway controls cell proliferation in developmental tissues, which is normally suppressed in developed tissues and reactivated in cancer cells. 19 This result is consistent with the traditional standpoint that rapidly proliferating cancer cells are more sensitive to radiation treatment. Thus, we postulated that inactivation of Hippo/YAP signaling pathway is critical for maintaining radiation resistance in normal astrocytes and radiationresistant glioma cells.
suppression of hippo/YaP signaling pathway induces radiation resistance
To investigate the role of Hippo/YAP signaling pathway in differential responses between normal astrocytes and glioma cells, we first measured the activation status of Hippo signaling pathway in normal astrocyte and glioma cell lines. As YAP is the main signaling output of Hippo pathway, we first determined the level of phosphorylated YAP (inactive YAP) in glioma cell lines (U251 and SNB19) and HA normal astrocyte cell line. As shown in Figure 5A , results from Western blot indicated that the levels of phosphorylated YAP were lower in U251 and SNB19 cells than in HA cells. In addition, we found that the levels of nuclear YAP were higher in U251 and SNB19 cells than in HA cells ( Figure 5B ). Moreover, quantitative real-time polymerase chain reaction (qRT-PCR) analysis showed that the mRNA levels of YAP target genes (CTGF, AREG) were higher in U251 and SNB19 cells than in HA cells ( Figure 5C 
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Differential radiation response between has and glioma cells dataset downloaded from R2: Genomics Analysis and Visualization Platform, we found that a high expression of YAP predicts poor outcome of patients with glioma ( Figure S8A ). These results demonstrated that the Hippo/YAP signaling is more active in glioma cells than in normal astrocytes. Next, we investigated the effect of radiation on Hippo/ YAP signaling pathway in HA and U251 cells. As shown in Figure 5D , radiation treatment increased the level of phosphorylated YAP in HA cells but decreased it in U251 cells. In addition, the levels of nuclear YAP were decreased in radiation-treated HA cells but were increased in radiationtreated U251 cells ( Figure 5E ). Moreover, analysis from qRT-PCR indicated that radiation treatment decreased the mRNA levels of YAP target genes in HA cells but increased them in U251 cells ( Figure 5F ). These results confirmed the previous finding that Hippo/YAP signaling pathway is oppositely regulated by radiation in HA and U251 cells.
To further confirm the role of Hippo/YAP signaling pathway in radiation resistance of glioma cells, we generated YAP-knockdown U251 and SNB19 stable cell lines by lentivirus-mediated shRNA expression system ( Figure S8B ). As shown in Figure 5G , the growth curves showed that YAP depletion decreased the proliferation of U251 and SNB19 cells, which suggested that Hippo/YAP signaling pathway is at least partially necessary for the proliferation of glioma cells. Then, the effect of YAP depletion on radiation sensitivity of U251 and SNB19 cells was measured. As shown in Figure 5H and I, results from both cell viability assay and colony formation assay showed that silence of YAP reduced the cytotoxic effects of radiation on glioma cells. Similar results were observed in U251 and SNB19 cells treated with YAP inhibitor (verteporfin; Figure S8C) . Collectively, these results demonstrated that suppression of Hippo/YAP signaling induces radiation resistance in glioma cells.
Discussion
In this study, we characterized and compared the transcriptome profiles of radiation-treated and nontreated HA normal astrocytes and U251 glioma cells. The signaling pathways related to differential responses between normal astrocytes and U251 glioma cells were revealed. In addition, the role of Hippo/YAP signaling pathway in intrinsic and acquired radiation resistance was investigated. Our work provided novel insights about the underlying mechanism of differential responses between normal astrocytes and glioma cells and acquired radiation resistance of glioma cells.
Radiation treatment is the major therapeutic method in glioma treatment. 3 The rationale of using radiation to treat glioma is based on the fact that the proliferating glioma cancer cells are more sensitive to the radiation treatment than normal brain cells. 7 Thus, understanding the underlying mechanism of differential responses between normal 
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Differential radiation response between has and glioma cells astrocytes and glioma cells would be useful to improve the therapeutic efficiency. Meanwhile, acquisition of radiation resistance occurs frequently in glioma cells, and in some cases, induced radiation-resistant glioma cells and normal astrocytes share similar mechanism of radiation-resistance. 7 Hence, it is important to understand the differential radiation responses between normal astrocytes and glioma cells to improve glioma treatment.
In this study, we chose HA and U251 cells as normal astrocyte and glioma cell models, respectively. HAs are normal human cells derived from human cerebral cortex with typical star-like morphology. 20 Because of its high degree of biological relevance, HA cell line serves as an ideal model for studies of human neurological pathways. On the other hand, U251 cell line was derived from a malignant glioblastoma tumor and had been previously used in the studies of cell signaling, drug or radiation response and cancer stem cells in glioma. 21 By using the cell viability assay, we found that HA cells were more resistant to radiation treatment ( Figure S1 ), which confirmed that HA and U251 cells could serve as normal astrocyte and glioma cell models to investigate the differential responses between normal brain and glioma cells.
mRNA and lncRNA profiles of radiation-treated and non treated HA and U251 cells were generated by nextgeneration sequencing. By comparative analysis of these profiles, we identified several classic pathways involved in radiation response of astrocytes and glioma cells. For example, genes involved in response to external stimulus were found to be differentially expressed in both cell lines after radiation treatment, which confirmed the effect of the radiation treatment in these cells. In addition, genes associated with ion binding were changed by radiation treatment in HA and U251 cells. This result is consistent with the previous observation that radiation produces free radicals and changes the expression of ion-binding proteins in the cells. 7 Moreover, several key pathways involved in cancer development and therapeutic resistance have been found in the results from pathway analysis of DEGs, such as focal adhesion, Hippo signaling, and gap junction pathways, which indicated their roles in radiation response of astrocytes and glioma cells.
Hippo/YAP signaling pathway is an evolutionally conserved cascade, which controls organ size by regulation of proliferation, cell cycle and apoptosis of the cells. 22 The key components of Hippo signaling consist of MTS1/2 and LATS1/2. In developed organs, Hippo signaling phosphorylates and limits YAP, the major output of Hippo/YAP signaling, in the cytoplasm. However, in developing organs or cancer cells, the Hippo signaling pathway is suppressed and the dephosphorylated YAP translocates into the nucleus and serves as a transcriptional coactivator to promote gene expression by forming a complex with TEAD transcription factors. The association between Hippo/YAP signaling and radiation resistance has been reported in several studies. YAP is a double-edged sword in response to DNA damage. 22 YAP could induce apoptosis and reduce proliferation of the cells by stabilization of p73 in HCT116 and H1299 cells after cisplatin-induced DNA damage. 23 However, in some cells, YAP protects cells from DNA damage-induced apoptosis and promotes proliferation with unrepaired DNA through IGF-2 and AKT signaling pathways. 24 In our study, we found the YAP activity was reduced in radiation-resistant normal astrocytes and was slightly enhanced in radiation-sensitive glioma cells ( Figure 5D-F) . Subsequent experiments with YAP-knockdown U251 and SNB19 cells demonstrated that YAP plays an important role in the proliferation of glioma cells ( Figure 5G ) and knockdown of YAP induces radiation resistance in glioma cells ( Figure 5H and I). This information indicated that suppression of YAP is one of the mechanisms underlying acquired radiation resistance of glioma cells. Furthermore, we found that YAP inhibitor induced radiation resistance in U251 and SNB19 cells ( Figure S8C ), which indicated that YAP inhibitor could not be used in combination with radiation for glioma treatment. However, the role of YAP suppression in radiation resistance of glioma cells still needs further study.
In addition, we found that several lncRNAs were oppositely regulated in HA and U251 cells. Several studies reported the association between lncRNAs and radiation resistance of cancer. For example, Fan et al 25 reported the role of lncRNAs in glucose metabolism in cancer, which partially contributes to radiation resistance. Jiang et al 26 reported that downregulation of lncRNA TUG1 enhances radiosensitivity in bladder cancer via suppressing HMGB1 expression. However, the functional roles of lncRNAs in radiation resistance of glioma cells are still being revealed.
Conclusion
In summary, we characterized and compared the transcriptome profiles of radiation-treated and nontreated normal astrocytes and glioma cells. Key pathways involved in intrinsic and acquired radiation resistance were identified. We also demonstrated that suppression of YAP activity is at least one of the mechanisms underlying radiation resistance in glioma. Our work is useful for improvement of our understanding about the differential responses between normal astrocytes and glioma cells and would be useful for advancement of glioma therapy.
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